Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead ...

The firm owned 70,353 shares of the company’s stock after selling 7,726 shares during the quarter. UBS AM a distinct business ...

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23.

Leerink Partners started coverage on Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective for the company. Leerink ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

The projected annual revenue for Mind Medicine is 0MM. The projected annual non-GAAP EPS is -3.18. Commodore Capital holds 8,000K shares representing 10.91% ownership of the company. In its prior ...